Morus alba L. (Sangzhi) Alkaloids Promote Insulin Secretion, Restore Diabetic β-Cell Function by Preventing Dedifferentiation and Apoptosis

Lei Lei1,2,†, Yi Huan1,2,3,†, Quan Liu1,2,3, Caina Li1,2,3, Hui Cao1,2,3, Wenming Ji1,2, Xuefeng Gao1,2, Yaxin Fu1,2, Pingping Li1,2,3, Ruiping Zhang1,2,4, Zeper Abliz1,2,4, Yuling Liu1,2,5, Shuainan Liu1,2,3* and Zhufang Shen1,2,3

1Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Key Laboratory of Polymorphic Drugs of Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Diabetes Research Center of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 4CAMS Key Laboratory of Molecular Mechanism and Target Discovery of Metabolic Disorder and Tumorigenesis, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background: Morus alba L. (Sangzhi) alkaloids (SZ-A), extracted from the Chinese herb Morus alba L. (mulberry twig), have been shown to ameliorate hyperglycemia in type 2 diabetes and have been approved for diabetes treatment in the clinic. However, their versatile pharmacologic effects and regulatory mechanisms are not yet completely understood.

Purpose: This study explored the protective effects of SZ-A on islet β cells and the underlying mechanism.

Methods: Type 2 diabetic KKAy mice were orally administered SZ-A (100 or 200 mg/kg, once daily) for 11 weeks, and oral glucose tolerance, insulin tolerance, intraperitoneal glucose tolerance and hyperglycemia clamp tests were carried out to evaluate the potency of SZ-A in vivo. The morphology and β-cell dedifferentiation marker of KKAy mouse islets were detected via immunofluorescence. The effect of SZ-A on glucose-stimulated insulin secretion was investigated in both the islet β-cell line MIN6 and mouse primary islets. Potential regulatory signals and pathways in insulin secretion were explored, and cell proliferation assays and apoptosis TUNEL staining were performed on SZ-A-treated MIN6 cells.

Results: SZ-A alleviated hyperglycemia and glucose intolerance in type 2 diabetic KKAy mice and improved the function and morphology of diabetic islets. In both MIN6 cells and primary islets, SZ-A promoted insulin secretion. At a normal glucose level, SZ-A decreased AMPKα phosphorylation, and at high glucose, SZ-A augmented the cytosolic calcium concentration. Additionally, SZ-A downregulated the β-cell dedifferentiation marker.

Abbreviations: DAB, 1,4-dideoxy-1,4-imino-D-arabinitol; DNJ, 1-deoxynojirimycin; FAG, fagomine; PA, palmitic acid; SZ-A, Morus alba L. (Sangzhi) alkaloids.
INTRODUCTION

Type 2 diabetes is a great threat to human health worldwide. In diabetic patients, because of hyperglycemia, many chronic complications, such as angio-cardiopathy, retinopathy, nephropathy, and neuropathy, often occur. Progressive reductions in β-cell function and mass comprise the central pathogenic mechanism of type 2 diabetes. Although many therapeutics have been deployed to combat hyperglycemia, few of them directly target β-cell pathogenesis besides of GLP-1 analogs, such as liraglutide (Santilli et al., 2017), and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin (Xu et al., 2008).

The progression of β-cell dysfunction includes not only defective insulin secretion but also β-cell mass reduction, which results from β-cell apoptosis, the failure of existing β cells to proliferate, and β-cell dedifferentiation under metabolic stress such as hyperglycemia, hyperlipidemia and chronic inflammation (Sun and Han, 2020; Ying et al., 2020; Amo-Shinoki et al., 2021). However, given the reversibility of β cells, the reduction in β-cell mass should not be completely ascribed to apoptosis (Marselli et al., 2014). Recently, increasing evidence has suggested that β-cell failure may be mainly due to increased dedifferentiation (Cinti et al., 2016; Ishida et al., 2017; Sun et al., 2019). Therefore, preventing dedifferentiation or promoting β-cell redifferentiation after the occurrence of dedifferentiation may be another method for type 2 diabetes therapy.

The traditional Chinese medicine Morus alba L. (Sangzhi) alkaloids (SZ-A) tablets have been approved by the China National Medical Products Administration for type 2 diabetes mellitus (T2DM) treatment in China. Qu et al. (Qu et al., 2021) demonstrated that SZ-A tablets possess effective hypoglycemic effects with few adverse events, suggesting good safety in clinical trials. SZ-A contains three major effective fractions, namely, 1-deoxyojirimycin (DNJ), 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) and fagomine (FAG) (Yang et al., 2015; Yang et al., 2017), which are extracts from the Chinese herb Morus alba L. (mulberry twig), the dried young branch of Morus alba L. SZ-A not only inhibits the activity of α-glucosidases, especially sucrase and maltase, in vitro (Liu et al., 2019) but also ameliorates intestinal flora imbalance and hyperglycemia in diabetic KKAY mice (Liu et al., 2015; Liu et al., 2021; Yuling). However, the protective effect and mechanism of SZ-A on β-cell function in the progression of diabetes remain to be further identified.

Our observations support a novel role for SZ-A in β-cell function and mass. We show that SZ-A may act on more targets than glucosidase. It not only promotes β-cell insulin secretion but also ameliorates β-cell loss by preventing β-cell dedifferentiation and apoptosis.

MATERIAL AND METHODS

Drug and Reagents
1-Deoxynojirimycin (DNJ) and fagomine (FAG) were purchased from MedChem Express (HY-14860 and HY-13005, USA). 1,4-Dideoxy-1,4-imino-D-arabinitol (DAB) was purchased from Sigma (D1542, USA). Morus alba L. (Sangzhi) alkaloid (SZ-A) powder (Lot number: 201708008; the total polyhydroxy alkaloids content in SZ-A powder is approximately 63%, which includes 39% DNJ, 10.5% FAG, and 7% DAB, as shown in Supplementary Figure S1) was synthesized and provided by Beijing Wehand-bio Pharmaceutical Co. Ltd. (Beijing, China).

Animal Experimental Design
C57BL/6J mice (male, 14 weeks) were fed a normal diet and comprised the normal group (Nor group). KKAy mice (male, 14 weeks) were fed high-fat diets (45% of kcal from fat; D12451; Research Diets, USA). After 4 weeks, the KKAy mice were randomly divided into three groups (Con group and two doses of SZ-A-treated groups, 10 mice per group) according to the levels of fasting blood glucose, triglycerides, total cholesterol, body weight and the percentage of increasing blood glucose level at 30 min after glucose (2.0 g/kg) overloading (Diagram of animal experiment was shown as Figure 1A). The SZ-A groups were orally administered SZ-A (100 mg/kg, SZ-A_100; 200 mg/kg, SZ-A_200) once per day. The Nor group and Con group were treated with vehicle. All animals were housed in communal cages at 23 ± 1°C on a 12-h light-dark cycle with free access to food and water.

Blood glucose was tested in the 2nd week. The oral glucose tolerance test (OGTT), insulin tolerance test (ITT) and intraperitoneal glucose-stimulated insulin secretion test (IPGSIST) were carried out consecutively on the 5th, 6th, and 8th weeks. The hyperglycemia clamp test was conducted in the 11th week. Then, the mice were sacrificed via cervical dislocation, and the pancreas was separated and subsequently fixed with formalin. The experiments were conducted following the “3R” principles and the standards for laboratory animals (GB14925-2001 and MOST 2006a) established by the People’s Republic of China. The animal protocol was approved by the Institutional

Keywords: morus alba L. (Sangzhi) alkaloids, type 2 diabetes, islet β cells, insulin secretion, apoptosis, dedifferentiation
Animal Care and Use Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China).

OGTT, ITT and IPGSIST
The mice were fasted for 6 h, and blood was obtained from the tail for the fasting blood glucose test. For the OGTT, blood samples were acquired at 0, 30, 60 and 120 min after oral glucose overload (2.0 g/kg) for the blood glucose test. For the ITT, mice were hypodermically injected with insulin (0.4 IU/kg), and subsequently, blood was taken from the tail at 40 and 90 min. For the IPGSIST, blood samples were acquired at 0 and 30 min after intraperitoneal injection of glucose (2.0 g/kg) for blood glucose and insulin tests.

The Hyperglycemic Clamp Test
The mice were anesthetized with amobarbital sodium after fasting overnight, and then 5% (w/v) glucose was perfused into the jugular vein through a peristaltic pump. During the first 1 min, a glucose bolus (100 mg/kg) was given. Blood was obtained from the tail at 0, 2, 5, 10, and 15 min after glucose loading for the phase I insulin secretion test. Subsequently, glucose was microperfused persistently until the blood glucose level remained steady at 14.0 ± 0.5 mM. The whole testing process took approximately 2.0–2.5 h, during which blood was obtained at 60, 100, and 120 min for the phase II insulin secretion test.

Morphology and Immunohistochemistry of Islets From KKA\textsuperscript{Y} Mice Treated With SZ-A
The fixed pancreases of KKA\textsuperscript{Y} mice were embedded in paraffin. Tissues were sliced to 5 μm for morphology analyses. Some sections were stained with hematoxylin-eosin to observe the morphology of islets under a microscope. Others were immunostained with rabbit anti-glucagon antibody (1:200, ab92517, Abcam, USA), rabbit anti-ALDH1A3 antibody (1:100, NBP2-15339, NOVUS, USA), and rat anti-insulin antibody (1:200, MAB1417, R&D Systems, USA). The secondary antibodies were Alexa Fluor 488 donkey anti-rabbit IgG (1:200, A-21206, Invitrogen, USA) and Alexa Fluor 594 donkey anti-rat IgG (1:200, A-11007, Invitrogen, USA). Then, the tissues were mounted utilizing mounting medium with DAPI (ZLI-9557, ZSGB-BIO, China). Finally, the tissues were visualized by confocal laser scanning microscopy (CLSM) (Leica Microsystems, Germany). ImageJ software was used to analyze the picture. The area percentage of β-cell/islet and α-cell/islet were calculated via the insulin-positive or glucagon-positive area in one islet divided by the islet area. The ratio of ALDH1A3-positive β cells/β cells were calculated via the both ALDH1A3 and insulin-positive area divided by insulin-positive area in the islet.

Cells and Primary Islet Preparation
The mouse β-cell line MIN6 was a gift from Professor Xiao Han at Nanjing Medical University, and the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 25 mM glucose) supplemented with 15% fetal bovine serum (FBS) (Chen et al., 2016). Mouse islets were isolated from C57BL/6J mice (male, 24 ± 2 g) and diabetic KKA\textsuperscript{Y} mouse model (male, 38 ± 2 g) using the collagenase V (C9263, Sigma, Germany) perfusion method and were cultured in RPMI-1640 medium supplemented with 10% FBS as reported previously (Lei et al., 2015).

Glucose-Stimulated Insulin Secretion Assay
MIN6 cells and mouse islets were prepared to test insulin secretion in response to low and high concentrations of glucose. MIN6 cells were plated in 96-well plates (5 × 10\textsuperscript{4} well) and starved for 1 h in Krebs buffer (2.8 mM glucose) with or without different concentrations of SZ-A, DNJ, FAG or DAB. Then, the cells were cultured for another 1 h in new Krebs buffer containing 2.8 mM or 16.8 mM glucose combined...
with SZ-A, DNJ, FAG, DAB or vehicle. Ten islets were transferred to new Krebs buffer containing 2.8 or 16.8 mM glucose and were cultured for 1 h after fasting for 1 h in Krebs buffer with 2.8 mM glucose, which was combined with SZ-A, DNJ, FAG, DAB or vehicle. The supernatant was collected for the insulin test using the Mouse Ultrasensitive Insulin ELISA Kit (80-INNSMU-E10, ALPCO, USA). MIN6 cells and mouse islets were used for quantitative protein determination with BCA reagents (P1511, APPLiGEN, China).

Estimation of the Free Cytosolic Ca\(^{2+}\) Concentration
MIN6 cells in 96-well plates were cultured with 25, 50, and 100 μg/ml SZ-A; 10 μg/ml FAG; 10 μg/ml DAB; or vehicle for 1 h. The cells were then loaded with the Ca\(^{2+}\)-sensing fluorescent probe Fluo-4 AM (F14201, Invitrogen, USA) for 30 min at 37°C. The internal calcium concentration ([Ca\(^{2+}\)]\(_{i}\)) was measured using a Multimode Microplate Reader (Synergy 2, BIO-TEK, USA) through time-series recording of the fluorescent signal. A 5-min basal recording was acquired when the cells were in Krebs buffer containing 2.8 mM glucose. For stimulation, the cells were perfused with Krebs buffer containing elevated glucose concentration (16.8 mM) combined with SZ-A or vehicle. The changes in the MIN6 cell [Ca\(^{2+}\)]\(_{i}\) were recorded for 20 min after stimulation.

Measurement of cAMP Produced in MIN6 Cells
Intracellular cAMP ([cAMP])\(_{i}\) was measured with a LANCE cAMP Detection Kit (AD0262, PerkinElmer, USA) through time-resolved fluorescence resonance energy transfer (TR-FRET) technology. MIN6 cells were preincubated for 1 h in Krebs buffer containing 2.8 mM glucose and different concentrations of SZ-A or vehicle. Then, both Alexa Fluor 647-cAMP antibody solution and stimulation solution containing 25 μM isobutyl methylxanthine (312460, J&K, China) and different concentrations of SZ-A or vehicle were added to each well and cultured for 30 min. The europium chelate of the Eu-SA/b-cAMP tracer was subsequently added to test the cAMP production of MIN6 cells through a multilabel reader (Envision 2104, PerkinElmer, USA).

High Glucose and Palmitic Acid Treatment
For high glucose (Glc) and palmitic acid (PA) treatment, MIN6 cells were incubated in DMEM with 15% FBS, 33 mM glucose and 0.25 mM palmitic acid. The blank control cells were incubated in DMEM with 15% FBS, 25 mM glucose and 8 mM mannitol (63559, Sigma, USA).

Cell Proliferation Assay
MIN6 cells were seeded at 3 × 10\(^4\)/100 μl per well in 96-well plates and incubated under normal conditions. The next day, they were treated with 25, 50, or 100 μg/ml SZ-A or vehicle for 24 h. At the same time, high glucose- and palmitic acid-treated MIN6 cells were co-incubated with different concentrations of SZ-A, DNJ, FAG, DAB or vehicle for 24 h. Cell proliferation was detected by EdU labeling according to the recommended protocol of the assay kit (C0071, Beyotime, China). The cells were fixed with 4% paraformaldehyde, and the nuclei were labeled with Hoechst 33342. The fluorescence signal was detected at 530/25 nm (EdU signal) and 460/40 nm (Hoechst 33342 signal) with a multifunctional microplate reader (Synergy 2, BioTek, USA) and calculated as the ratio of Edu to Hoechst 33342.

TUNEL Assay
High glucose- and palmitic acid-treated MIN6 cells were coincubated with different concentrations of SZ-A, DNJ, FAG, DAB or vehicle for 72 h and fixed with 4% paraformaldehyde. The TUNEL assay was performed according to the recommended procedure of the TransDetect® In Situ Fluorescein TUNEL Cell Apoptosis Detection Kit (FA201-01, TransGen Biotech, China). Finally, the cells were mounted utilizing mounting medium with DAPI (ZLI-9557, ZSGB-BIO, China). The images were visualized by inverted fluorescence microscopy (Olympus, Japan). The data are presented as the ratio of TUNEL/DAPI.

Caspase 3 Activity Assay
High glucose- and palmitic acid-treated MIN6 cells were coincubated with different concentrations of SZ-A, DNJ or vehicle for 24 h. Then, the activity of caspase 3 was tested using Caspase-Glo®3/7 Assays (G8981, Promega, USA). The signal was detected with a multifunctional microplate reader (Synergy 2, BioTek, USA).

Western Blot Analysis
The islets of KKA\(^{Y}\) mice were incubated in RPMI-1640 medium containing vehicle or 100 μg/ml SZ-A for 24 h. MIN6 cells were fasted for 1 h in Krebs buffer (2.8 mM glucose) with or without different concentrations of SZ-A, FAG, or DAB. Then, they were cultured for another 1 h in new Krebs buffer containing 2.8 mM or 16.8 mM glucose combined with SZ-A, FAG, DAB or vehicle. High glucose- and palmitic acid-treated MIN6 cells were coincubated with different concentrations of SZ-A, DNJ or vehicle for 24 h.

Islets or MIN6 cells were homogenized in RIPA lysis buffer (C1053; APPLiGEN, China) containing protease inhibitors (P1265; APPLiGEN, China) and phosphatase inhibitors (P1260; APPLiGEN, China). Protein (10 μg) from each sample was resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes for immunoblotting. Rabbit anti-phospho-AMPKα (1:1000, 2535s), rabbit anti-AMPKα (1:1000, 2532s), rabbit-phospho-Erk (1:1000, 9101s), rabbit anti-Erk (1:1000, 9102s), and rabbit anti-HSP90 (1:1000, 4877s) were purchased from Cell Signaling Technology (USA). Goat anti-rabbit IgG/HRP (1:5000, ZDR-5306) was purchased from ZSGB-BIO (China).

Quantitative PCR
The islets of KKA\(^{Y}\) mice were incubated in RPMI-1640 medium containing vehicle or 100 μg/ml SZ-A for 24 h. RNA was isolated using TRIzol Reagent (15596018, Life Technology, USA), and
cDNA was synthesized using TransScript® One-Step gDNA Removal and cDNA Synthesis SuperMix (AT311, TransGen Biotech, China) for gene expression analysis. Quantitative PCR (qPCR) was performed with TransStart Tip Green qPCR SuperMix (AQ141–04, TransGen Biotech, China) using the primers shown in Table 1.

### Statistical Analysis
GraphPad Prism 8 was used for all statistical analyses. Two experimental groups were analyzed by Student's t test. Multiple groups were compared by one-way analysis of variance (ANOVA) followed by Dunnett’s t test or two-way ANOVA with Tukey’s test depending on the experiments. Differences were considered statistically significant at $p < 0.05$.

### RESULTS

#### SZ-A Alleviates Hyperglycemia and Glucose Intolerance in Type 2 Diabetic KKA\(\text{Y}\) Mice

The type 2 diabetic KKA\(\text{Y}\) mice have a similar metabolic syndrome phenotype as humans and exhibit hyperglycemia, hyperinsulinemia, hyperlipidemia and obesity. We have reported that SZ-A ameliorates glucose and lipid metabolism in KKA\(\text{Y}\) mice (Liu et al., 2021). In this study, we again identified that non-fasting and fasting blood glucose was reduced significantly with SZ-A treatment (Figures 1C,D), which may be ascribed to the increased insulin secretion and sensitivity. In order to identify these further, OGTT, ITT and IPGSIST were carried out sequentially. The OGTT and ITT showed that SZ-A alleviated hyperglycemia after oral glucose load (Figures 1E,F) and IP injection of insulin (Figures 1G,H) in a dose-dependent manner. Notably, 200 mg/kg SZ-A could ameliorate glucose tolerance significantly. At the same time, body weight in the two SZ-A treatment groups decreased significantly (Figure 1B).

### SZ-A Amends Islet β-Cell Dysfunction in Type 2 Diabetic KKA\(\text{Y}\) Mice

IPGSIST was carried out in KKA\(\text{Y}\) mice. We observed that at either 0 min or 30 min after IP injection of glucose (2.0 g/kg),SZ-A significantly decreased blood glucose (Figures 2A,B). In addition, blood insulin at 0 min was significantly reduced by SZ-A, but insulin secretion after glucose overload was promoted significantly in the SZ-A group (Figures 2A,B). Subsequently, the hyperglycemic clamp test showed that SZ-A could raise the first-phase insulin secretory response to glucose by 86.17% (AUC0–15 min) compared with that of the Con group (Supplementary Figures S2B,C).

The morphology of islets was depicted by staining glucagon (green) in α cells and insulin (red) in β cells. The islet architecture of the Con group was damaged, as evidenced by the slightly diminished β cells as well as by the augmented and diffusely distributed α cells. Despite all of these changes, in the SZ-A treated islets, more β cells were interspersed among the islets, and a cells tended to be located toward the edge of the islets (Figure 2C), which were associated with significantly increased β-cell area and decreased α-cell area (Figures 2D,E). At the same time, the ALDH1A3+ cells were significantly diminished in the SZ-A group (Figures 2F,G). Moreover, some cells in the central area of the islets displayed vacuolar degeneration and necrosis in mice of the Con group, but the islet morphology in the SZ-A group was normal (Supplementary Figure S2A).

#### SZ-A Stimulates Insulin Secretion in the Mouse β-Cell Line MIN6 and Mouse Primary Islets

To investigate the possible role of SZ-A in the β-cells insulin secretion, both the mouse β-cell line MIN6 and mouse primary islets were treated with SZ-A. In both MIN6 cells (Figure 3A) and KKA\(\text{Y}\) mouse islets (Figure 3C), SZ-A at 100 μg/ml promoted insulin secretion regardless of the glucose concentration (2.8 mM or 16.8 mM). In C57BL/6J mouse islets, SZ-A mainly enhanced insulin secretion at 16.8 mM glucose (Figure 3B). In addition, three major effective fractions, namely, DNJ, FAG and DAB, showed different efficacies on insulin secretion in β cells. Among them, DAB and FAG facilitated insulin secretion in MIN6 cells, but DNJ did not (Supplementary Figure S3A). In addition, DAB and FAG facilitated insulin secretion in C57BL/6J mouse islets and
FIGURE 2 | SZ-A ameliorates diabetic β-cell dysfunction in type 2 diabetic KKAy mice. (A,B) An intraperitoneal glucose-stimulated insulin secretion test (IPGSST) was executed in KKAy mice after treating with SZ-A (200 mg/kg) for 8 weeks (n = 5 mice per group). (A) Blood glucose and insulin levels at 0 min before injection of glucose. (B) Blood glucose and the percentage of increased blood insulin at 30 min after glucose (2.0 g/kg) load. (C–G) Immunohistochemistry of the pancreas of KKAy mice in the Con group and SZ-A (200 mg/kg) group (n = 5 mice per group). β Cells were labeled with insulin antibody (red), α cells were labeled with glucagon antibody (green), dedifferentiated cells were labeled with ALDH1A3 antibody (green). (D) The percentage of β-cell/islet area; (E) the percentage of α-cell/islet area; and (G) the ratio of ALDH1A3-positive β cells/β cells. All data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, vs. the Con group.
KKA\textsuperscript{y} mouse islets, respectively (Supplementary Figures S3B,C). However, SZ-A has a greater ability to stimulate insulin secretion in \(\beta\) cells than any of its constituents.

**Increased \([\text{Ca}^{2+}]_i\), and Decreased AMPK\(\alpha\) Phosphorylation Are Involved in Insulinotropic Effect of SZ-A in MIN6 Cells**

Glucose facilitates insulin secretion through changes in the free \([\text{Ca}^{2+}]_i\), and \([\text{cAMP}]_i\), so we examined the actions of SZ-A on \([\text{Ca}^{2+}]_i\), and \([\text{cAMP}]_i\), in MIN6 cells. In MIN6 cells, elevating the glucose concentration from 2.8 to 16.8 mM initiated a marked rise in \([\text{Ca}^{2+}]_i\), and \([\text{cAMP}]_i\). However, in the presence of 2.8 mM glucose, SZ-A had no effect on \([\text{Ca}^{2+}]_i\). At a glucose concentration of 16.8 mM, changes in \([\text{Ca}^{2+}]_i\) were observed after SZ-A treatment (Figure 3D). At the same time, 100 \(\mu\)g/ml SZ-A significantly decreased AMPK\(\alpha\) phosphorylation levels (Figures 3E,F) at 2.8 mM glucose. However, in the presence of 2.8 mM or 16.8 mM glucose, SZ-A did not cause an increase in \([\text{cAMP}]_i\), (Supplementary Figure S4A). In addition, two of the major effective fractions, that is, FAG and DAB, modulated the glucose-dependent increases in \([\text{Ca}^{2+}]_i\), (Supplementary Figure S4B) and inhibited AMPK phosphorylation at 2.8 mM glucose (Supplementary Figure S4C).

**SZ-A Ameliorates \(\beta\)-Cell Dedifferentiation in Type 2 Diabetic KKA\textsuperscript{y} Mouse Islets**

Islet \(\beta\)-cell dedifferentiation has been suggested to participate to the \(\beta\)-cell failure (Zhang and Liu, 2020), and Aldh1a3 was reported as a marker of \(\beta\)-cell dedifferentiation (Kim-Muller et al., 2016). In KKA\textsuperscript{y} mice, the Aldh1a3 expression level was significantly increased in islet \(\beta\) cells compared with normal mice (Supplementary Figure S5). The expression level of Aldh1a3 was inhibited significantly in KKA\textsuperscript{y} mouse islets treated with SZ-A (Figures 4A–C). Moreover, in islet cells, SZ-A increased \(\beta\)-cell identifying genes such as \textit{Ins1}, \textit{Ins2}, \textit{Nkx2.2} and \textit{Pax4} and decreased \(\beta\)-cell excluding genes such as \textit{Gcg} and \textit{MafB} (Figure 4D).

**SZ-A Attenuates Apoptosis, Accompanied With Downregulated Erk1/2 Phosphorylation and Caspase 3 Activity in High Glucose- and Palmitic Acid-Treated MIN6 Cells**

In addition to dedifferentiation, apoptosis was another cause to \(\beta\)-cell mass reduction. High glucose and palmitic acid treatment (24 h) inhibited proliferation, and if treatment was prolonged to 72 h, apoptosis were recognized by
increased TUNEL-positive cells. SZ-A did not influence cell proliferation in basic culture medium (25 mM glucose) but significantly reversed the growth inhibition of MIN6 cells induced by high glucose and palmitic acid (Figure 4E).

Furthermore, SZ-A at concentrations of 50 and 100 μg/ml significantly decreased the number of TUNEL-positive cells after 72 h of high glucose and palmitic acid treatment (Figures 4F, G). Interestingly, among the three major fractions of SZ-A,
DNJ but not FAG and DAB showed a similar effect (Supplementary Figure S6).

Furthermore, SZ-A significantly attenuated the elevated Erk1/2 phosphorylation level and caspase 3 activity under high glucose- and palmitic acid-induced stress conditions (Figures 5A–C). Similarly, DNJ, one of the major fractions of SZ-A, decreased both Erk1/2 phosphorylation and caspase 3 activity (Supplementary Figure S7).

**DISCUSSION**

SZ-A, as a natural medicine with effective components (no less than 50% alkaloids), was approved as a clinical therapeutic for type 2 diabetic patients in 2020 in China. As reported in a phase IIIa clinical study, SZ-A can ameliorate hyperglycemia and reduce HbA1c in type 2 diabetic patients (Qu et al., 2021). In addition, in our previous study, we showed that SZ-A maintains the intestinal flora balance and promotes GLP-1 secretion (Liu et al., 2021). Given that β-cell failure is related to the transition from prediabetes to diabetes, improved β-cell function has a major role in preventing type 2 diabetes. Our previous research pointed out that SZ-A may ameliorate β-cell dysfunction (Liu et al., 2021). However, the substantial effects and underlying mechanism of SZ-A on islet β-cell function need to be identified further. Herein, we demonstrate that SZ-A not only promotes insulin secretion in β cells but also preserves β cells mass by preventing β-cell dedifferentiation and apoptosis.

Many studies have provided evidence that changes in the cytoplasmic concentrations of calcium and/or cAMP influence insulin secretion by β cells (Lei et al., 2015; Tengholm and Gylfe, 2017). Similarly, we found that SZ-A could augment the glucose-dependent changes in the [Ca²⁺], of β cells but had no effect on the [cAMP]ₐ, which suggests that SZ-A-induced increases in [Ca²⁺], and that improvements in Ca²⁺-dependent exocytosis may be the possible mechanism by which it promotes glucose-stimulated insulin secretion. Recently, the biological role of AMPK in β cells has garnered considerable interest. Indeed, as blood glucose concentrations rise from fasting levels to feeding levels, the AMPK phosphorylation level in the islets falls (Fu et al., 2009; Swisa et al., 2015), which coincides with our results wherein the phosphorylation of AMPK was downregulated when glucose concentrations rose from 2.8 to 16.8 mM. In our research, we show that SZ-A decreases AMPK phosphorylation levels at 2.8 mM glucose but has no obvious influence at 16.8 mM glucose, which may be because the phosphorylation of AMPK has been almost completely inhibited by high glucose concentrations. The effect of SZ-A on AMPK activity may partially explain its promotion of glucose secretion at 2.8 mM glucose. However, the real mechanism by which SZ-A regulates changes in [Ca²⁺], and AMPK activity still needs to be studied further.

Hyperglycemia is an important characteristic of type 2 diabetes. In addition, hyperlipidemia is often a concomitant symptom. The concurrence of elevated glucose and fatty acid levels will cause synergistic glucolipotoxicity on islet β cells, which leads to β-cells dysfunction, including inhibition of β-cell proliferation, impaired insulin gene expression, decreased insulin secretion, dedifferentiation and apoptosis (Pascoe et al., 2012; Pan et al., 2016; Lytrivi et al., 2020).

In both animal models and patients, dedifferentiated β cells exist, and aldehyde dehydrogenase 1a3 (ALDH1A3) can be used as a dedifferentiation marker (Cinti et al., 2016; Kim-Muller et al., 2016; Sun et al., 2019; Amo-Shiinoki et al., 2021). Therefore, inducing dedifferentiated β cells to return to mature and functional β cells is a very important area of research. Some research has confirmed that dedifferentiated β cells could redifferentiate back into normal β cells, which is a drug-targetable process. Calorie restriction could prevent and reverse β-cell dedifferentiation in db/db mice (Ishida et al., 2017). Insulin supplementation during the early stage of type 2 diabetes was an effective therapy (Wang et al., 2014). Inhibition of TGF-β signaling reversed β-cell dedifferentiation in Sel1L⁻/⁻ mice (Shrestha et al., 2020). However, the therapies to reverse β-cell dedifferentiation in the clinic are still at the initial stage. Fortunately, our study showed that SZ-A dampens β-cell dedifferentiation and restores insulin-positive β cells. In addition, a subset of dedifferentiated β cells could undergo conversion into other endocrine cell types, such as Gcg⁰ cells (Talchait et al., 2012). SZ-A increases the suppression of β-cell-specific genes (Ins1, Ins2, Nkx2.2, and Pax4) but decreases the upregulation of α-cell-specific genes (Gcg and MafB) in islets of type 2 diabetic KKA⁵ mice. This demonstrates that the conversion of dedifferentiated cells to mature β cells may exist after SZ-A treatment, which possibly explains the restoration of islet β-cell function and morphology in KKA⁵ mice. However, its effect on patient islets still needs to be identified in the clinic.

In addition, β-Cell apoptosis contributes significantly to the loss of β cells in type 2 diabetes (Mandrup-Poulsen, 2001; Mathis et al., 2001). In our glucolipotoxic MIN6 cell model, SZ-A attenuated apoptosis, which may partially be explained by the increased Erk1/2 phosphorylation and caspase 3 activity induced by high glucose and palmitic acid. Erk elicits apoptosis by activating caspase 3 (Zhuang et al., 2007). Li (Li et al., 2022) also reported that mulberry leaf alkaloids and one of its active components (DNJ) could inhibit the increased apoptotic protease activity of caspase 3 in GLUTag cells. However, the ability of SZ-A to prevent β-cell apoptosis was first presented by us, and it is probably the main factor responsible for the restoration of β-cell mass and function in type 2 diabetes.

Apart from this, we also found that three major alkaloids, namely, DNJ, FAG and DAB, show different effects on the protective action of β cells. DNJ is inclined to ameliorate glucolipotoxic β-cell dysfunction, while FAG and DAB preferentially promote insulin secretion. However, the potency of each of these alkaloids is less than that of SZ-A.

**CONCLUSION**

Our findings indicate that SZ-A, as a new type 2 diabetes therapy, promotes insulin secretion and provides more protection of β cells by preventing dedifferentiation in vivo and in vitro, and also prevents apoptosis in high glucose and palmitic acid treated
insulinoma cell line. These observations offer supportive evidence and widen the clinical application of SZ-A.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by The Institutional Animal Care and Use Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China).

AUTHOR CONTRIBUTIONS

LL: conceptualization, methodology, formal analysis, investigation, writing-original draft and funding acquisition. YH: methodology, formal analysis, investigation, writing-review and editing and funding acquisition. QL: investigation, funding acquisition, writing-review and editing. RZ: investigation. ZA: investigation, funding acquisition, writing-review and editing. XG: investigation. YF: investigation. PL: investigation, funding acquisition. CL: data curation. HC: data curation. WJ: supervision and funding acquisition. ZH: supervision and funding acquisition. TZ: supervision. YZ: supervision. SL: supervision, writing-review and editing and funding acquisition.

REFERENCES

Amo-Shinoki, K., Tanabe, K., Hoshii, Y., Matsui, H., Harano, R., Fukuda, T., et al. (2021). Islet Cell Dedifferentiation Is a Pathologic Mechanism of Long- Standing Progression of Type 2 Diabetes. *JCI insight.* 6, e143791. doi:10.1172/jci.insight.143791

Chen, F., Sha, M., Wang, Y., Wu, T., Shan, W., Liu, J., et al. (2016). Transcription Factor Ets-1 Links Glucotoxicity to Pancreatic β Cell Dysfunction through Inhibiting PDX-1 Expression in Rodent Models. *Diabetologia.* 59, 316–324. doi:10.1007/s00125-015-3805-3

Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., et al. (2016). Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes. *J. Clin. Endocrinol. Metab.* 101, 1044–1054. doi:10.1210/jc.2015-2860

Fu, A., Ng, A. C., Depatie, C., Wijesekara, N., He, Y., Wang, G. S., et al. (2009). Loss of Lkb1 in Adult Beta Cells Increases Beta Cell Mass and Enhances Glucose Tolerance in Mice. *Cell. Metab.* 10, 285–295. doi:10.1016/j.cmet.2009.08.008

Ishida, E., Kim-Muller, J. Y., and Accili, D. (2017). Pair Feeding, but Not Insulin, Phlorizin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in Db/db Mice. *Diabetes.* 66, 2092–2101. doi:10.2337/db16-1213

Kim-Muller, J. Y., Fan, J., Kim, Y. J., Lee, S. A., Ishida, E., Blaney, W. S., et al. (2016). Aldehyde Dehydrogenase 1a3 Defines a Subset of Failing Pancreatic β Cells in Diabetic Mice. *Nat. Commun.* 7, 12631. doi:10.1038/ncomms12631

Lei, L., Liu, Q., Liu, S., Huan, Y., Sun, S., Chen, Z., et al. (2015). Antidiabetic Potential of a Novel Dual-Target Activator of Glucokinase and Peroxisome Proliferator Activated Receptor-γ. *Metabolism.* 64, 1250–1261. doi:10.1016/j.metabol.2015.06.014

FUNDING

The work was supported by the Natural Science Foundation of Beijing Municipality (No. 7202137), the CAMS Fundamental Research Funds for the Central Universities (No. 3332020040), the CAMS Initiative for Innovative Medicine (CAMS-12M) (No. 2021-12M-026), the National Natural Science Foundation of China (No. 81973379 and 81803597), Beijing Outstanding Young Scientist Program (BJJWZYJH01201910023028), the State Key Laboratory of Bioactive Substance and Function of Natural Medicines (No. GTZA201807).

ACKNOWLEDGMENTS

The authors are very thankful to the manufacturer of SZ-A (Guangxi Wehand-bio Pharmaceutical Co. Ltd.), the suppliers of SZ-A (Beijing Wehand-bio Pharmaceutical Co. Ltd.). And we would like to thank Dr. Zhihua Liu (Department of Research & Development of Beijing Wehand-bio Pharmaceutical Co. Ltd.) for the technical assistance of providing the content data and chromatogram of components in the SZ-A during this work. Thank Professor Xiao Han in Nanjing Medical University for giving MIN6 cell line. Thank Dr. Wenqiang Gan in our institute for the help in immunostaining analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.841981/full#supplementary-material

Li, J. S., Ji, T., Su, S. L., Zhu, Y., Chen, X. L., Sha, M., Li, G., et al. (2012). Mulberry Leaves Ameliorate Diabetes via Regulating Metabolic Profiling and AGES/RAGE and P38 MAPK/NF-κB Pathway. *J. Ethnopharmacol.* 133, 617–624. doi:10.1016/j.jep.2011.09.023

Liu, Q., Liu, S., Cao, H., Ji, W., Li, C., Huan, Y., et al. (2021). Ramulus Mori (Sangzhi) Alkaloids (SZ-A) Ameliorate Glucose Metabolism Accompanied by the Modulation of Gut Microbiota and Ileal Inflammatory Damage in Type 2 Diabetic KKAy Mice. *Front. Pharmacol.* 12, 278. doi:10.3389/fphar.2021.62400

Liu, Y. L., Shen, Z. F., Chen, Z., Wang, R. Y., Xia, X. J., Chen, Y. T., et al. (2015). The Use of the Effective Fraction of Alkaloids from mulberry Twig in Preparing Hypoglycemic Agents (United States Patent).

Liu, Z., Yang, Y., Dong, W., Liu, Q., Wang, R., Pang, J., et al. (2019). Investigation on the Enzymatic Profile of Mulberry Alkaloids by Enzymatic Study and Molecular Docking. *Molecules.* 24, 1776. doi:10.3390/molecules24091776

Lytrivi, M., Castell, A. L., Politou, V., and Cnop, M. (2020). Recent Insights into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. *J. Mol. Biol.* 432, 1514–1534. doi:10.1016/j.jmb.2019.09.016

Mandrup-Poulsen, T. (2001). Beta-Cell Apoptotic Stimuli and Signaling. *Diabetes.* 50 Suppl 1 (50 Suppl. 1), S58–S63. doi:10.2337/diabetes.50.2007.s58

Marselli, L., Suleiman, M., Masini, M., Campani, D., Bugliani, M., Syed, F., et al. (2014). Are We Overestimating the Loss of Beta Cells in Type 2 Diabetes? *Diabetologia.* 57, 362–365. doi:10.1007/s00125-013-3098-3

Mathis, D., Vence, L., and Benoist, C. (2001). Beta-Cell Death during Progression to Diabetes. *Nature.* 414, 792–798. doi:10.1038/414792a

Pan, Y., Li, G., Zhong, H., Chen, M., Chen, T., Gao, L., et al. (2016). RIG-1 Inhibits Pancreatic β Cell Proliferation through Competitive Binding of Activated Src. *Sci. Rep.* 6, 28914. doi:10.1038/srep28914
